Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus ORAGRAFIN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus ORAGRAFIN CALCIUM.
DIONOSIL AQUEOUS vs ORAGRAFIN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
Oragrafin Calcium is a diagnostic radiocontrast agent that contains calcium ipodate. It acts by absorbing X-rays due to its high iodine content (61% iodine by weight). After oral administration, it is absorbed and excreted into the bile, allowing radiographic visualization of the gallbladder and biliary ducts. It may also enhance CT imaging of the liver and biliary tree.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
Oral: 5 mL (1 packet) orally, may repeat in 30-60 minutes if needed. Maximum 2 doses per procedure. Rectal: 100-200 mL of a 1:1 dilution with water as a retention enema.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 1.2 hours (0.7–2.0 hours) in patients with normal renal function. May be prolonged in renal impairment (up to 18 hours in severe impairment).
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Primarily renal: 90% of absorbed dose excreted unchanged in urine within 24 hours; <10% via feces. Biliary excretion is negligible in the absence of hepatobiliary obstruction.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent